

1 Clinical, Environmental, and Genetic Risk Factors for Substance Use Disorders:

2 Characterizing Combined Effects across Multiple Cohorts

3 Peter B. Barr, Ph.D.^{1,2}, Morgan N. Driver, B.S.³, Sally I-Chun Kuo, Ph.D.⁴,
4 Mallory Stephenson, M.S.⁵, Fazil Aliev, Ph.D.⁶, Richard Karlsson Linnér, Ph.D.⁷,
5 Jesse Marks⁸, Andrey P. Anokhin, Ph.D.⁹, Kathleen Bucholz, Ph.D.⁹, Grace Chan, Ph.D.^{10,11},
6 Howard J. Edenberg, Ph.D.^{12,13}, Alexis C. Edwards, Ph.D.⁵, Meredith W. Francis, Ph.D.⁹,
7 Dana B. Hancock⁸, K. Paige Harden, Ph.D.^{14,15}, Chella Kamarajan, Ph.D.¹,
8 Jaakko Kaprio M.D., Ph.D.¹⁶, Sivan Kinreich, Ph.D.¹, John Kramer, Ph.D.¹¹,
9 Samuel Kuperman, M.D.¹¹, Antti Latvala, Ph.D.¹⁷, Jacquelyn L. Meyers, Ph.D.^{1,2},
10 Abraham A. Palmer, Ph.D.^{18,19}, Martin H. Plawecki M.D., Ph.D.²⁰, Bernice Porjesz, Ph.D.¹,
11 Richard J. Rose, Ph.D.²¹, Marc A. Schuckit, M.D.¹⁸, Jessica E. Salvatore, Ph.D.⁴,
12 and Danielle M. Dick, Ph.D.⁶

13
14 ¹ Department of Psychiatry and Behavioral Sciences, SUNY Downstate Health Sciences University,
15 Brooklyn, NY, USA.

16 ² VA New York Harbor Healthcare System, Brooklyn, NY, USA.

17 ³ Department of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, VA, USA.

18 ⁴ Department of Psychiatry, Robert Wood Johnson Medical School, Rutgers University, Piscataway, NJ,
19 USA.

20 ⁵ Virginia Institute for Psychiatric and Behavioral Genetics, Department of Psychiatry, Virginia
21 Commonwealth University, Richmond, VA, USA.

22 ⁶ Rutgers Addiction Research Center, Rutgers University, Piscataway, NJ, USA.

23 ⁷ Department of Economics, Leiden University, Leiden, The Netherlands.

24 ⁸ Biostatistics and Epidemiology Division, RTI International, Research Triangle Park, NC, USA

25 ⁹ Department of Psychiatry, School of Medicine, Washington University in St. Louis, St Louis, MO, USA.

26 ¹⁰ Department of Psychiatry, School of Medicine, University of Connecticut, Farmington, CT, USA.

27 ¹¹ Department of Psychiatry, Carver College of Medicine, University of Iowa, Iowa City, IA, USA

28 ¹² Department of Medical and Molecular Genetics, School of Medicine, Indiana University, Indianapolis,
29 IN, USA

30 ¹³ Department of Biochemistry and Molecular Biology, School of Medicine, Indiana University,
31 Indianapolis, IN, USA

32 ¹⁴ Department of Psychology, University of Texas at Austin, Austin, TX, USA.

33 ¹⁵ Population Research Center, University of Texas at Austin, Austin, TX, USA.

34 ¹⁶ Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland

35 ¹⁷ Institute of Criminology and Legal Policy, University of Helsinki, Helsinki, Finland

36 ¹⁸ Department of Psychiatry, University of California San Diego, La Jolla, CA, USA.

37 ¹⁹ Institute for Genomic Medicine, University of California San Diego, La Jolla, CA, USA.

38 ²⁰ Department of Psychiatry, School of Medicine, Indiana University, Indianapolis, IN, USA

39 ²¹ Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN, USA

40
41 Corresponding author: Peter B. Barr

42 Department of Psychiatry and Behavioral Sciences

43 SUNY Downstate Health Sciences University

44 450 Clarkson Ave, MSC 1203, Brooklyn, NY 11203

45 e-mail: peter.barr@downstate.edu.

46
47 Submission for: Molecular Psychiatry

48 Running Header: Characterizing Risk for SUDS across Multiple Cohorts

49 Word count abstract: 244; Word count text body: 3,518

50 Figures and Tables: 3 Tables, 2 Figures

51 **ABSTRACT**

52 Substance use disorders (SUDs) incur serious social and personal costs. Risk for SUDs
53 is complex, ranging from social conditions to individual genetic variation. We examined whether
54 models that include a clinical/environmental risk index (CERI) and polygenic scores (PGS) are
55 able to identify individuals at increased risk of SUD in young adulthood across four longitudinal
56 cohorts for a combined sample of $N = 15,134$. Our analyses included participants of European
57 ($N_{EUR} = 12,659$) and African ($N_{AFR} = 2,475$) ancestries. SUD outcomes included: 1) alcohol
58 dependence, 2) nicotine dependence; 3) drug dependence, and 4) any substance dependence.
59 In the models containing the PGS and CERI, the CERI was associated with all three outcomes
60 (ORs = 1.37 – 1.67). PGS for problematic alcohol use, externalizing, and smoking quantity were
61 associated with alcohol dependence, drug dependence, and nicotine dependence, respectively
62 (OR = 1.11 – 1.33). PGS for problematic alcohol use and externalizing were also associated
63 with any substance dependence (ORs = 1.09 – 1.18). The full model explained 6% - 13% of the
64 variance in SUDs. Those in the top 10% of CERI and PGS had relative risk ratios of 3.86 - 8.04
65 for each SUD relative to the bottom 90%. Overall, the combined measures of clinical,
66 environmental, and genetic risk demonstrated modest ability to distinguish between affected
67 and unaffected individuals in young adulthood. PGS were significant but added little in addition
68 to the clinical/environmental risk index. Results from our analysis demonstrate there is still
69 considerable work to be done before tools such as these are ready for clinical applications.

70 INTRODUCTION

71 Substance use disorders (SUDs) are associated with substantial costs to affected
72 individuals, their families, and society. An estimated 107107,000 Americans died as the result of
73 an overdose in 2021 ¹. In 2016, alcohol use contributed 4.2% to the global disease burden and
74 other drug use contributed 1.3% ². Excessive alcohol use and illicit drug use cost the United
75 States an annual \$250 billion ³ and \$190 billion ⁴ respectively. Given the substantial human and
76 economic costs of substance misuse and disorders, understanding the combined impact of
77 important risk factors across multiple levels of analysis has important public health implications.

78 Substance use disorders are complex phenomena, and the development of substance
79 related problems can be attributed to factors ranging from broader social and economic
80 conditions to individual genetic variation ^{5–10}. Prior research using a multifactorial index of
81 clinical and environmental risk factors (e.g., childhood disadvantage, family history of SUD,
82 childhood conduct problems, childhood depression, early exposure to substances, frequent use
83 during adolescence) found it useful in identifying those with persistent SUDs ¹¹.

84 More recently, polygenic scores (PGS), which aggregate risk for a trait across the
85 genome using information from genome-wide association studies (GWAS), were robustly
86 associated with substance use ¹² and substance related problems ¹³ across adolescence and
87 into young adulthood. However, though robustly associated, current PGS do poorly in identifying
88 individuals affected by SUDs ¹⁴. To date, there is limited work on the combined impact of
89 genetic, environmental, and clinical risk factors for SUDs. Prior work combining individual
90 genetic variants and clinical features outperformed clinical features alone ¹⁵, but individual
91 variants have limited predictive power. In other medical conditions, such as melanoma ¹⁶ or
92 ischemic stroke ¹⁷, combining clinical and genetic risk factors showed improvement predicting
93 risk for a specific outcome over models using individual risk factors.

Running Header: Characterizing Risk for SUDS across Multiple Cohorts

94 In the current study, we examine the joint association of early life clinical/environmental
95 risk factors and PGS with SUDs in early adulthood across four longitudinal cohorts: the National
96 Longitudinal Study of Adolescent to Adult Health (Add Health); the Avon Longitudinal Study of
97 Parents and Children (ALSPAC); the Collaborative Study on the Genetics of Alcoholism
98 (COGA); and the youngest cohort of the Finnish Twin Cohort Study (FinnTwin12). These
99 samples include population-based cohorts from three countries (United States, England, and
100 Finland) and a predominantly high-risk sample. Two of the samples (COGA and Add Health) are
101 ancestrally diverse. We focus on early adulthood as this is a critical period for the development
102 and onset of SUDs ¹⁸. Our research questions are guided by the understanding that risk factors
103 for SUDs range across multiple levels of analysis.

104 **METHODS**

105 *Samples*

106 *Add Health* is a nationally representative longitudinal study of adolescents followed into
107 adulthood in the United States ¹⁹. Data have been collected from Wave I when respondents
108 were between 11-18 (1994-1995) to Wave V (2016-2018) when respondents were 35-42. The
109 current analysis uses data from Waves I, II, and Wave IV.

110 *ALSPAC* is an ongoing, longitudinal population-based study of a birth cohort in the
111 (former) Avon district of Southwest England ²⁰⁻²³. Pregnant female residents with an expected
112 date of delivery between April 1, 1991 and December 31, 1992 were invited to participate (N =
113 14,541 pregnant women, 80% of those eligible). This analysis uses data up to the age 24
114 assessment (details of all the data that is available through a searchable, web-based tool:
115 <http://www.bristol.ac.uk/alspac/researchers/our-data/>).

116 *COGA* is a family-based sample consisting of alcohol dependent individuals (identified
117 through treatment centers across the United States), their extended families, and community

Running Header: Characterizing Risk for SUDS across Multiple Cohorts

118 controls (N ~16,000)^{24,25}. We use a prospective sample of offspring of the original COGA
119 participants (baseline ages 12-22, N = 3,573) that have been assessed biennially since
120 recruitment (2004-2019)²⁶.

121 *FinnTwin12* is a population-based study of Finnish twins born 1983–1987 identified
122 through Finland’s Central Population Registry. A total of 2,705 families (87% of all identified)
123 returned the initial family questionnaire late in the year in which twins reached age 11²⁷. Twins
124 were invited to participate in follow-up surveys when they were ages 14, 17, and approximately
125 22.

126 Each cohort includes a wide range of social, behavioral, and phenotypic data measured
127 across the life course. The SUD measures were derived from the corresponding young adult
128 phases of data collection in each cohort (mean ages ~ 22 - 28). A full description of each
129 sample is presented in the supplementary information (section 2).

130 *Measures*

131 *Lifetime Diagnosis of Substance Use Disorder*

132 We constructed measures of lifetime SUD diagnosis based on the data that were
133 available in each of the samples, defined as meeting criteria for four, non-mutually exclusive
134 categories of substance dependence: 1) alcohol dependence; 2) nicotine dependence; 3) drug
135 dependence (inclusive of drugs such as cannabis, cocaine, opioids, sedatives, etc.); and 4) any
136 substance dependence (alcohol, nicotine, or drug). Our analyses focused primarily on DSM-IV
137 as this diagnostic system was most consistently used across all samples. There was one
138 exception: in each of the samples, nicotine dependence was measured using a cutoff of 7 or
139 higher on the Fagerstrom Test for Nicotine Dependence (FTND)²⁸. Where possible, we drew
140 measures of substance dependence from data collected during young adulthood to try and
141 maintain temporal ordering between SUD diagnoses and measured risk factors.

Running Header: Characterizing Risk for SUDS across Multiple Cohorts

142 *Clinical/Environmental Risk Index*

143 We created a clinical/environmental risk index (CERI) considering a variety of
144 established risk factors for SUD (Table 1). The CERI included ten validated early life risk factors
145 associated with later development of SUDs, including: low childhood socioeconomic status
146 (SES), family history of SUD, early initiation of substance use, childhood internalizing problems,
147 childhood externalizing problems, frequent drinking in adolescence, frequent smoking in
148 adolescence, frequent cannabis use in adolescence, peer substance use, and exposure to
149 trauma/traumatic experiences^{11,29,30}. We dichotomized each risk factor (present vs not present)
150 and summed them into an index for each person ranging from 0 to 10, providing a single
151 measure of aggregate risk. Dichotomizing these items allowed us to harmonize measures
152 across each sample in an interpretable manner. A full list of how each measure is defined within
153 each of the samples is available in the supplementary information (section 3).

154 *Polygenic Scores*

155 We constructed polygenic scores (PGS), which are aggregate measures of the number
156 of risk alleles individuals carry weighted by effect sizes from GWAS summary statistics, from six
157 recent GWAS of SUDs and comorbid conditions including: 1) externalizing problems (EXT)³¹; 2)
158 major depressive disorder (MDD)³²; 3) problematic alcohol use³³ (ALCP); 4) alcohol
159 consumption (drinks per week, ALCC)^{34,35}; 5) cigarettes per day/FTND (CPD)^{34,36}; and 6)
160 schizophrenia (SCZ)^{37,38}. We focused on these PGS, specifically, because: 1) SUDs show
161 strong genetic overlap with other externalizing³⁹⁻⁴¹, internalizing^{32,42}, and psychotic disorders
162^{33,43,44}; 2) both shared and substance-specific genetic risk are associated with later SUDs⁴⁵⁻⁴⁷;
163 and 3) substance use and SUDs have only partial genetic overlap^{48,49}. Therefore, our PGS
164 cover a spectrum of genetic risk for SUDs, using the most current and well-powered results for
165 each of the listed domains (see supplementary information section 4 for a detailed description).

Running Header: Characterizing Risk for SUDS across Multiple Cohorts

166 GWAS have been overwhelmingly limited to individuals of European ancestries^{50,51}.
167 Importantly, PGS derived from GWAS of one ancestry do not always transport into other
168 ancestral populations^{52,53}. We therefore used PRS-CSx⁵⁴, a new method that combines
169 information from well-powered GWAS (typically of European ancestries) and ancestrally
170 matched GWAS to improve the predictive power of PGS in the African ancestry samples from
171 Add Health and COGA. PRS-CSx integrates GWAS summary statistics across multiple input
172 populations and employs a Bayesian approach to correct GWAS summary statistics for the non-
173 independence of SNPs in linkage disequilibrium (LD) with one another⁵⁴. For participants of
174 European ancestries, we used the EUR derived PRS-CSx results, while we used the EUR+AFR
175 meta-analyzed results for the African ancestry participants. See the supplementary information
176 (section 5) for details.

177 *Analytic Strategy*

178 We pooled all the data for analysis using a fixed effects integrative data analytic (IDA)
179 approach⁵⁵. The IDA approach is more powerful than traditional meta-analyses when one has
180 access to raw data for each of the contributing samples. Our approach to harmonization and
181 pooling was as follows. First, we defined the measures and cutoffs to be used in each of the
182 samples, creating the CERI, PGS, and SUD outcomes at the cohort level. Second, within each
183 cohort, we regressed each PGS on age, age², sex, sex*age, sex*age², and the first 10 ancestral
184 PCs (specific to each sample) to account for population stratification in the PGS. Next, we
185 pooled all the data for analysis. We included cohort as a fixed effect for each of the six cohorts
186 (4 samples, of which two were split by ancestry) in subsequent analyses. Additionally, we
187 included age of last observation and sex as covariates.

188 We estimated a series of nested logistic regression models with the pooled data: 1) a
189 baseline model (sex, age, and cohort), 2) a genetic risk model (baseline + PGS), 3) a

Running Header: Characterizing Risk for SUDS across Multiple Cohorts

190 clinical/environmental risk model (baseline + CERI), and 4) a combined risk model (baseline +
191 PGS + CERI). Because COGA and FT12 included a large number of related individuals, we
192 adjusted for familial clustering using cluster-robust standard errors⁵⁶. To assess the predictive
193 accuracy of each model, we took the difference in pseudo- R^2 ($\Delta Pseudo-R^2$)⁵⁷, between the
194 baseline and corresponding models. Finally, we calculated the discriminatory power of the
195 combined model using the area under the curve (AUC) from a receiver operating characteristic
196 (ROC) curve. To ensure the robustness of our results, we included a variety of checks to ensure
197 that no single cohort in the IDA was unduly influencing the results. Our analytic strategy was
198 preregistered on the Open Science Framework (<https://osf.io/etbw8>). Deviations from the
199 preregistration are described in the supplementary information (section 6).

200 RESULTS

201 Table 2 contains the descriptive statistics for each of the cohorts and ancestries. Each
202 cohort had similar proportions of females (~51% - 56%). The mean ages ranged from ~22 to
203 ~29 years of age. The COGA cohorts (both European and African ancestries) reported the
204 highest rates of SUD, an expected finding given the nature of the sample (highly selected for
205 SUDs). Add Health participants generally had higher rates of SUD than ALSPAC or FinnTwin12,
206 but lower than COGA. Finally, ALSPAC and FinnTwin12 reported similar levels of alcohol,
207 nicotine, drug, and any substance dependence. COGA participants reported higher mean
208 values on the CERI. The remaining cohorts report relatively similar rates of risk factor exposure.

209 Table 3 presents the results from the *PGS only*, *CERI only*, and *combined* models for
210 each outcome. Three of the six PGS were associated with the SUD outcomes in the *PGS only*
211 model. EXT was associated with each of the SUD outcomes (EXT OR = 1.18 – 1.50); ALCP
212 was associated with alcohol dependence and any substance dependence (ALCP OR = 1.10 –
213 1.13); and CPD was associated with nicotine dependence (CPD OR = 1.33). In the *CERI only*

Running Header: Characterizing Risk for SUDS across Multiple Cohorts

214 models, the CERI was consistently associated across each of the SUD categories (ORs = 1.37
215 – 1.67). When we combined the PGS and CERI into the same model, the CERI remained
216 significant across SUDs and was largely unchanged (ORs = 1.35 – 1.65). EXT remained
217 associated with drug dependence (OR = 1.11) and nicotine dependence (OR = 1.33), ALCP
218 remained associated alcohol dependence (OR = 1.12), and CPD remained associated with
219 nicotine dependence (OR = 1.31). Both EXT and ALCP remained associated with any
220 substance dependence diagnosis (ORs = 1.09 – 1.18). Overall, the combined model explained
221 5.9%, 12.6%, 13.1%, and 12.8% of the variance in alcohol dependence, nicotine dependence,
222 drug dependence, and any substance dependence, respectively.

223 Figure 1 (Panel A) presents the raw prevalence for each outcome across counts of the
224 CERI. The proportion of those meeting criteria for SUDs among those reporting 3 or more, 5 or
225 more, and 7 or more risk factors surpassed lifetime prevalence estimates from nationally
226 representative samples for drug dependence, alcohol dependence, and nicotine dependence,
227 respectively⁵⁸. Panel B depicts the prevalence of each category of SUD across several mutually
228 exclusive categories: 1) those in the bottom 90% of both the CERI and all PGS (averaged
229 across the six scores); 2) those in the top 10% of the CERI but the bottom 90% of the PGS
230 distribution; 3) those in the top 10% of the PGS distribution and the bottom 90% of the CERI;
231 and 4) those in the top 10% of both PGS and the CERI. There is an increase in risk across
232 those with elevated genetic risk, clinical/environmental risk, and both. Those in the top 10% of
233 both PGS and CERI had the highest prevalence of each of the SUDs, though the error bars
234 overlap with the estimates from those in the top 10% of the risk index, alone. Compared to
235 those in the bottom 90% on both, those in the to the top 10% of both have a relative risk of 3.86
236 (95% CI = 3.20, 4.65) for alcohol dependence, 6.11 (95% CI = 4.84, 7.72) for nicotine
237 dependence, 8.04 (95% CI = 6.92, 9.36) for drug dependence, and 4.05 (95% CI = 3.64, 4.51)
238 for any substance dependence.

Running Header: Characterizing Risk for SUDS across Multiple Cohorts

239 Finally, we considered the AUC for the combined model for each of the SUD categories.
240 Figure 2 presents the ROC curves for the full (CERI and PGS) and baseline (covariates only)
241 models for each SUD category. The AUC for each combined model was 0.74 for alcohol
242 dependence, 0.82 for nicotine dependence, 0.86 for drug dependence, and 0.78 for any
243 substance dependence. The overall change in AUC (from the baseline to the full model) that we
244 achieve when adding the CERI and PGS was modest ($\Delta\text{AUC} = 0.05 - 0.10$), and this
245 improvement was due in large part to the explanatory power of the CERI. ROC curves for the
246 CERI only and PGS only models are presented in Supplemental Figure 6.

247 *Sensitivity Analyses*

248 Lastly, we performed a variety of sensitivity analyses, including: 1) a leave-one-out
249 (LOO) analysis; 2) a sex-stratified analysis, and 3) ancestry-specific analysis. The results from
250 the LOO and sex-stratified analyses were largely similar to those from the main results. Results
251 in the European ancestry cohorts mirrored the main results, with the exception that the CPD
252 PGS was associated with “any substance dependence”. None of the PGS w associated with
253 SUDs in the African ancestry cohorts, but the effect sizes for the CERI were largely similar
254 across European and Africa ancestries (see Supplemental Tables S1-S3).

255 We also tested for interactions between the PGS and CERI and cohort (Add Health
256 EUR as the reference group). There were few significant interactions and no consistent patterns
257 in variation for PGS, though the CERI did show considerable variation across cohort
258 (Supplemental Table S4). Finally, we fit complimentary models using a random effects
259 approach, allowing the slopes for the PGS and CERI to vary randomly across cohort. Random
260 slopes for PGS did not consistently improve model fit, though a random slope for the CERI
261 consistently improved model fit (Supplemental Table S5). We compared the parameter

Running Header: Characterizing Risk for SUDS across Multiple Cohorts

262 estimates from the random effect models to the main analyses and results were largely
263 consistent (Supplemental Table S6).

264 **DISCUSSION**

265 Substance use disorders remain a serious threat to public health⁵⁹. In the current
266 analysis, we examined the combination of clinical, environmental, and genetic risk factors for
267 determining who is more likely to develop a SUD in early adulthood. We used previously
268 validated measures of environmental and clinical risk^{11,29,30} and polygenic scores for
269 externalizing problems³¹, major depressive disorder³², problematic alcohol use^{33,35}, alcohol
270 consumption^{34,35}, cigarettes per day/nicotine dependence^{34,36}, and schizophrenia^{37,38}. The
271 combination of genetic and social-environmental measures was significantly associated with the
272 development of SUDs. The overall association was strongest for drug dependence, followed by
273 any substance dependence, nicotine dependence, and alcohol dependence.

274 The CERI was the strongest association with each outcome. The proportion of those
275 meeting criteria for each SUD surpassed lifetime estimates in persons with 3 or more, 5 or
276 more, and 7 or more risk factors for drug dependence, alcohol dependence, and nicotine
277 dependence, respectively. The discriminatory power of the combined model (AUC = .74 - .86)
278 was similar to AUC estimates published in the original paper from which many of the risk index
279 items were derived (AUC ~ 0.80)¹¹. Interestingly, this risk index was originally developed for
280 identifying persons with persistent SUD through early mid-life (~age 40). In the current analysis
281 we demonstrated that the CERI in conjunction with demographic covariates and PGS does
282 equally well for those who meet criteria for any SUD by young adulthood.

283 The overall predictive power of the PGS alone was in the range of 1.1 – 3.7%. Only the
284 PGS for externalizing problems, problematic alcohol use, and cigarettes per day were
285 consistently associated with SUD outcomes. The PGS for externalizing problems was

Running Header: Characterizing Risk for SUDS across Multiple Cohorts

286 associated with drug dependence and nicotine dependence, the PGS for problematic alcohol
287 use PGS was associated with alcohol dependence, and both were associated with any
288 substance dependence. The PGS for cigarettes per day was only associated with nicotine
289 dependence. Overall, these results support prior evidence that genetic risk for SUDs consists of
290 a both shared and substance-specific variance^{31,41,47}.

291 Interestingly, even though the effect sizes were attenuated in the model, the PGS for
292 externalizing problems, problematic alcohol use, and cigarettes per day remained significantly
293 associated when we included the CERI, though the additional information the PGS provided
294 was minimal. Since the CERI also included many of the phenotypes each of the PGS measured
295 (e.g., childhood conduct disorder for externalizing, childhood depression for major depressive
296 disorder; and frequent alcohol use for alcohol consumption), part of this attenuation is likely due
297 to the inclusion of the actual phenotypes through which risk for some of these disorders is
298 expressed. PGS are also confounded by environmental variance⁵⁹ and the reduction in effect
299 sizes could be accounting for some of that confounding. PGS may add information beyond well-
300 known risk factors, which could prove useful when information on certain exposures or
301 behaviors is unavailable.

302 Further refinement of risk measures may improve our ability to develop screening
303 protocols for those at greater risk of developing substance-related problems. Early detection has
304 the potential to improve prevention efforts, as prior work suggests that those at highest risk of
305 substance misuse stand to benefit the most from prevention efforts⁶⁰. Ideally, screening tools
306 for SUD risk would include measures of social, clinical, and genetic risk factors, as each impacts
307 the development of SUDs^{5-7,61,62}. In the push for precision medicine, very often the focus is on
308 biological information, but social determinants of health are also critically important.

309 Currently, these tools are not ready for clinical use. If we reach the point where social,
310 clinical, and genetic information become sufficiently powerful, we must recognize that identifying
311 persons for early intervention carries a significant risk. Screening for social determinants has the

Running Header: Characterizing Risk for SUDS across Multiple Cohorts

312 potential for unintended consequences, including further stigmatization⁶³. Genetic information
313 has even more potential for abuse and stigmatization. Policy makers must ensure that there is
314 comprehensive legal protection against discrimination using any form of information.
315 Additionally, any attempt to use social, clinical, or genetic information for targeted intervention or
316 identification in a clinical setting must be done so in a patient-centered approach, rather than
317 any “one-size fits all” that exclude patients from their own healthcare decisions⁶⁴.

318 Our analysis has several important limitations. First, although we included individuals of
319 diverse ancestries, the PGS for our samples of African ancestries were severely underpowered
320 due to the small size of the discovery sample. Large-scale GWAS in diverse cohorts are vital to
321 ensuring that any benefit of precision medicine is shared equitably across the population⁶⁵.
322 Second, while distinct, ancestry is related to race-ethnicity, and with it, racism and racial
323 discrimination, some of the most profound social determinants of health⁶⁶. Our measure of
324 environmental risk may not fully capture risk factors that contribute to SUDs in populations
325 beyond non-Hispanic whites. Future studies should include racially relevant measures of risk
326 (e.g., experiences of interpersonal racism/discrimination, racial residential segregation) as well
327 as other social and environmental measures that are known risk factors for SUDs (e.g.,
328 neighborhood social conditions, alcohol outlet density). Further refinement of known risk factors
329 may allow for better prediction of those at risk of developing an SUD. Finally, while we tried to
330 ensure time order between risk factors and onset of disorder, some risk factors (particularly
331 adolescent substance use) could have occurred concurrently with diagnosis. Future work in
332 samples with risk factors measured before the initiation of substance use (such as the
333 Adolescent Brain Cognitive Development Study) will be important for replication efforts.

334 Recognizing that multiple social, clinical, and genetic factors contribute to risk for SUDs
335 is important as we move towards the goal precision medicine that benefits all segments of the
336 population. There is still much work to be done before tools such as these are useful in a clinical
337 setting. However, the results of this integrative data analysis provide initial evidence these risk

Running Header: Characterizing Risk for SUDS across Multiple Cohorts

338 factors contribute unique information to SUDs in early adulthood. Expanding our sources of
339 information (such as electronic health records, census data from home of record) and making
340 use of increasingly well-powered PGS will continue to improve our ability to identify those who
341 have the greatest risk of developing SUDs.

342 **ACKNOWLEDGEMENTS**

343 Research reported in this publication was supported by the National Institute on Alcohol Abuse
344 and Alcoholism and the National Institute of Drug Abuse of the National Institutes of Health
345 under award numbers R01AA015416, R01DA050721, R01DA042090, and K02AA018755; the
346 Academy of Finland (grants 100499, 205585, 118555, 141054, 265240, 308248, 308698 and
347 312073); and the Scientific and Technological Research Council of Turkey (TÜBİTAK) under
348 award number 114C117 (FA); and the Sigrid Juselius Foundation. The content is solely the
349 responsibility of the authors and does not necessarily represent the official views of any of the
350 funding bodies. This research also used summary data from the Psychiatric Genomics
351 Consortium (PGC), the Million Veterans Program (MVP), the GWAS and Sequencing
352 Consortium for Alcohol and Nicotine (GSCAN), UK Biobank, the Genomic Psychiatry Cohort
353 (GPC) and 23andMe, Inc. We would like to thank the many studies that made these consortia
354 possible, the researchers involved, and the participants in those studies, without whom this
355 effort would not be possible. We would also like to thank the research participants and
356 employees of 23andMe.

357 **The Externalizing Consortium:** Principal Investigators: Danielle M. Dick, Philipp Koellinger, K.
358 Paige Harden, Abraham A. Palmer. Lead Analysts: Richard Karlsson Linnér, Travis T. Mallard,
359 Peter B. Barr, Sandra Sanchez-Roige. Significant Contributors: Irwin D. Waldman. The
360 Externalizing Consortium has been supported by the National Institute on Alcohol Abuse and
361 Alcoholism (R01AA015416 - administrative supplement), and the National Institute on Drug

Running Header: Characterizing Risk for SUDS across Multiple Cohorts

362 Abuse (R01DA050721). Additional funding for investigator effort has been provided by
363 K02AA018755, U10AA008401, P50AA022537, as well as a European Research Council
364 Consolidator Grant (647648 EdGe to Koellinger). The content is solely the responsibility of the
365 authors and does not necessarily represent the official views of the above funding bodies. **Add**
366 **Health:** Add Health is directed by Robert A. Hummer and funded by the National Institute on
367 Aging cooperative agreements U01 AG071448 (Hummer) and U01AG071450 (Aiello and
368 Hummer) at the University of North Carolina at Chapel Hill. Waves I-V data are from the Add
369 Health Program Project, grant P01 HD31921 (Harris) from *Eunice Kennedy Shriver* National
370 Institute of Child Health and Human Development (NICHD), with cooperative funding from 23
371 other federal agencies and foundations. Add Health was designed by J. Richard Udry, Peter S.
372 Bearman, and Kathleen Mullan Harris at the University of North Carolina at Chapel Hill.
373 **ALSPAC:** We are extremely grateful to all the families who took part in this study, the midwives
374 for their help in recruiting them, and the whole ALSPAC team, which includes interviewers,
375 computer and laboratory technicians, clerical workers, research scientists, volunteers,
376 managers, receptionists, and nurses. The UK Medical Research Council and Wellcome (Grant
377 ref: 217065/Z/19/Z) and the University of Bristol provide core support for ALSPAC. This
378 publication is the work of the authors, and Peter Barr and Danielle Dick will serve as guarantors
379 for the contents of this paper. A comprehensive list of grants funding is available on the
380 ALSPAC website ([http://www.bristol.ac.uk/alspac/external/documents/grant-](http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf)
381 [acknowledgements.pdf](http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf)); This research was specifically funded by the Medical Research
382 Council (MRC) under grants MR/L022206/1, MR/M006727/1, and G0800612/86812; the
383 Wellcome Trust under grant 086684; and the National Institute on Alcohol Abuse and
384 Alcoholism under 5R01AA018333-05. GWAS data was generated by Sample Logistics and
385 Genotyping Facilities at Wellcome Sanger Institute and LabCorp (Laboratory Corporation of
386 America) using support from 23andMe. **COGA:** We thank The Collaborative Study on the
387 Genetics of Alcoholism (COGA), Principal Investigators B. Porjesz, V. Hesselbrock, T. Foroud;

Running Header: Characterizing Risk for SUDS across Multiple Cohorts

388 Scientific Director, A. Agrawal; Translational Director, D. Dick, includes eleven different centers:
389 University of Connecticut (V. Hesselbrock); Indiana University (H.J. Edenberg, T. Foroud, Y. Liu,
390 M.H. Plawecki); University of Iowa Carver College of Medicine (S. Kuperman, J. Kramer); SUNY
391 Downstate Health Sciences University (B. Porjesz, J. Meyers, C. Kamarajan, A. Pandey);
392 Washington University in St. Louis (L. Bierut, J. Rice, K. Bucholz, A. Agrawal); University of
393 California at San Diego (M. Schuckit); Rutgers University (J. Tischfield, R. Hart, J. Salvatore);
394 The Children's Hospital of Philadelphia, University of Pennsylvania (L. Almasy); Virginia
395 Commonwealth University (D. Dick); Icahn School of Medicine at Mount Sinai (A. Goate, P.
396 Slesinger); and Howard University (D. Scott). Other COGA collaborators include: L. Bauer
397 (University of Connecticut); J. Nurnberger Jr., L. Wetherill, X., Xuei, D. Lai, S. O'Connor,
398 (Indiana University); G. Chan (University of Iowa; University of Connecticut); D.B. Chorlian, J.
399 Zhang, P. Barr, S. Kinreich, G. Pandey (SUNY Downstate); N. Mullins (Icahn School of
400 Medicine at Mount Sinai); A. Anokhin, S. Hartz, E. Johnson, V. McCutcheon, S. Saccone
401 (Washington University); J. Moore, Z. Pang, S. Kuo (Rutgers University); A. Merikangas (The
402 Children's Hospital of Philadelphia and University of Pennsylvania); F. Aliev (Virginia
403 Commonwealth University); H. Chin and A. Parsian are the NIAAA Staff Collaborators. We
404 continue to be inspired by our memories of Henri Begleiter and Theodore Reich, founding PI
405 and Co-PI of COGA, and also owe a debt of gratitude to other past organizers of COGA,
406 including Ting- Kai Li, P. Michael Conneally, Raymond Crowe, and Wendy Reich, for their
407 critical contributions. This national collaborative study is supported by NIH Grant U10AA008401
408 from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and the National Institute
409 on Drug Abuse (NIDA). All code necessary to replicate this study is available upon request.

410 **ETHICS DECLARATIONS**

411 The authors have no conflicts of interest to declare.

Running Header: Characterizing Risk for SUDS across Multiple Cohorts

412

413 REFERENCES

- 414 1. U.S. Overdose Deaths In 2021 Increased Half as Much as in 2020 - But Are Still Up 15%.
415 https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2022/202205.htm.
- 416 2. Degenhardt, L. *et al.* The global burden of disease attributable to alcohol and drug use in
417 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of
418 Disease Study 2016. *The Lancet Psychiatry* **5**, 987–1012 (2018).
- 419 3. Sacks, J. J., Gonzales, K. R., Bouchery, E. E., Tomedi, L. E. & Brewer, R. D. 2010
420 National and State Costs of Excessive Alcohol Consumption. *American Journal of*
421 *Preventive Medicine* **49**, e73–e79 (2015).
- 422 4. National Drug Intelligence Center. *National drug threat assessment*. vol. 2019 (2011).
- 423 5. Verhulst, B., Neale, M. C. & Kendler, K. S. The heritability of alcohol use disorders: a
424 meta-analysis of twin and adoption studies. *Psychol Med* **45**, 1061–1072 (2015).
- 425 6. Verweij, K. J. H. *et al.* Genetic and environmental influences on cannabis use initiation
426 and problematic use: A meta-analysis of twin studies. *Addiction* **105**, 417–430 (2010).
- 427 7. Kendler, K. S., Jacobson, K. C., Prescott, C. A. & Neale, M. C. Specificity of Genetic and
428 Environmental Risk Factors for Use and Abuse/Dependence of Cannabis, Cocaine,
429 Hallucinogens, Sedatives, Stimulants, and Opiates in Male Twins. *American Journal of*
430 *Psychiatry* **160**, 687–695 (2003).
- 431 8. Galea, S., Nandi, A. & Vlahov, D. The Social Epidemiology of Substance Use.
432 *Epidemiologic Reviews* **26**, 36–52 (2004).
- 433 9. Barr, P. B. Neighborhood conditions and trajectories of alcohol use and misuse across
434 the early life course. *Health and Place* **51**, 36–44 (2018).
- 435 10. Barr, P. B., Silberg, J., Dick, D. M. & Maes, H. H. Childhood socioeconomic status and
436 longitudinal patterns of alcohol problems: Variation across etiological pathways in genetic
437 risk. *Social Science and Medicine* **209**, 51–58 (2018).

Running Header: Characterizing Risk for SUDS across Multiple Cohorts

- 438 11. Meier, M. H. *et al.* Which adolescents develop persistent substance dependence in
439 adulthood? Using population-representative longitudinal data to inform universal risk
440 assessment. *Psychol Med* **46**, 877–889 (2016).
- 441 12. Schaefer, J. D. *et al.* Associations between polygenic risk of substance use and use
442 disorder and alcohol, cannabis, and nicotine use in adolescence and young adulthood in
443 a longitudinal twin study. *Psychological Medicine* 1–11 (2021)
444 doi:10.1017/S0033291721004116.
- 445 13. Deak, J. D. *et al.* Alcohol and nicotine polygenic scores are associated with the
446 development of alcohol and nicotine use problems from adolescence to young adulthood.
447 *Addiction* **117**, 1117–1127 (2022).
- 448 14. Barr, P. B. *et al.* Using polygenic scores for identifying individuals at increased risk of
449 substance use disorders in clinical and population samples. *Translational Psychiatry* **10**,
450 196 (2020).
- 451 15. Kinreich, S. *et al.* Predicting risk for Alcohol Use Disorder using longitudinal data with
452 multimodal biomarkers and family history: a machine learning study. *Molecular Psychiatry*
453 **26**, 1133–1141 (2021).
- 454 16. Gu, F. *et al.* Combining common genetic variants and non-genetic risk factors to predict
455 risk of cutaneous melanoma. *Human Molecular Genetics* (2018)
456 doi:10.1093/hmg/ddy282.
- 457 17. O'Sullivan, J. W. *et al.* Combining clinical and polygenic risk improves stroke prediction
458 among individuals with atrial fibrillation. *medRxiv* 2020.06.17.20134163 (2020)
459 doi:10.1101/2020.06.17.20134163.
- 460 18. Kessler, R. C. *et al.* Lifetime prevalence and age-of-onset distributions of DSM-IV
461 disorders in the National Comorbidity Survey Replication. *Archives of General Psychiatry*
462 **62**, 593 (2005).

Running Header: Characterizing Risk for SUDS across Multiple Cohorts

- 463 19. Harris, K. M., Halpern, C. T., Haberstick, B. C. & Smolen, A. The National Longitudinal
464 Study of Adolescent Health (Add Health) sibling pairs data. *Twin Research and Human*
465 *Genetics* **16**, 391–398 (2013).
- 466 20. Boyd, A. *et al.* Cohort profile: The 'Children of the 90s'-The index offspring of the avon
467 longitudinal study of parents and children. *International Journal of Epidemiology* (2013)
468 doi:10.1093/ije/dys064.
- 469 21. Fraser, A. *et al.* Cohort profile: The avon longitudinal study of parents and children:
470 ALSPAC mothers cohort. *International Journal of Epidemiology* **42**, 97–110 (2013).
- 471 22. Harris, P. A. *et al.* Research electronic data capture (REDCap)-A metadata-driven
472 methodology and workflow process for providing translational research informatics
473 support. *Journal of Biomedical Informatics* **42**, 377–381 (2009).
- 474 23. Northstone, K. *et al.* The Avon Longitudinal Study of Parents and Children (ALSPAC): an
475 update on the enrolled sample of index children in 2019 [version 1; peer review: 2
476 approved]. *Wellcome Open Research* **4**, (2019).
- 477 24. Edenberg, H. J. The collaborative study on the genetics of alcoholism: An update. *Alcohol*
478 *Research and Health* **26**, 214–218 (2002).
- 479 25. Begleiter, H. The Collaborative Study on the Genetics of Alcoholism. *Alcohol Health and*
480 *Research World* **19**, 228 (1995).
- 481 26. Bucholz, K. K. *et al.* Comparison of Parent, Peer, Psychiatric, and Cannabis Use
482 Influences Across Stages of Offspring Alcohol Involvement: Evidence from the COGA
483 Prospective Study. *Alcoholism: Clinical and Experimental Research* **41**, 359–368 (2017).
- 484 27. Rose, R. J. R. J. *et al.* *FinnTwin12 Cohort: An Updated Review*. *Twin Research and*
485 *Human Genetics* vol. 22 (2019).
- 486 28. Heatherton, T. F., Kozlowski, L. T., Frecker, R. C. & Fagerstrom, K. O. The Fagerstrom
487 Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. *Br*
488 *J Addict* **86**, 1119–1127 (1991).

Running Header: Characterizing Risk for SUDS across Multiple Cohorts

- 489 29. Hughes, K. *et al.* The effect of multiple adverse childhood experiences on health: a
490 systematic review and meta-analysis. *The Lancet Public Health* (2017)
491 doi:10.1016/S2468-2667(17)30118-4.
- 492 30. Sher, K. J., Grekin, E. R. & Williams, N. A. The development of alcohol use disorders.
493 *Annual Review of Clinical Psychology* **1**, 493–523 (2005).
- 494 31. Karlsson Linner, R. *et al.* Multivariate genomic analysis of 1.5 million people identifies
495 genes related to addiction, antisocial behavior, and health. *Nature Neuroscience*.
- 496 32. Levey, D. F. *et al.* Bi-ancestral depression GWAS in the Million Veteran Program and
497 meta-analysis in >1.2 million individuals highlight new therapeutic directions. *Nature*
498 *Neuroscience* (2021) doi:10.1038/s41593-021-00860-2.
- 499 33. Zhou, H. *et al.* Genome-wide meta-analysis of problematic alcohol use in 435,563
500 individuals yields insights into biology and relationships with other traits. *Nature*
501 *Neuroscience* (2020) doi:10.1038/s41593-020-0643-5.
- 502 34. Liu, M. *et al.* Association studies of up to 1.2 million individuals yield new insights into the
503 genetic etiology of tobacco and alcohol use. *Nature Genetics* **51**, 237–244 (2019).
- 504 35. Kranzler, H. R. *et al.* Genome-wide association study of alcohol consumption and use
505 disorder in 274,424 individuals from multiple populations. *Nature Communications* **10**,
506 1499 (2019).
- 507 36. Quach, B. C. *et al.* Expanding the genetic architecture of nicotine dependence and its
508 shared genetics with multiple traits. *Nature Communications* **11**, (2020).
- 509 37. Trubetsky, V. *et al.* Mapping genomic loci implicates genes and synaptic biology in
510 schizophrenia. *Nature* **2022** 1–13 (2022) doi:10.1038/s41586-022-04434-5.
- 511 38. Bigdeli, T. B. *et al.* Genome-Wide Association Studies of Schizophrenia and Bipolar
512 Disorder in a Diverse Cohort of US Veterans. *Schizophrenia Bulletin* (2020)
513 doi:10.1093/schbul/sbaa133.

Running Header: Characterizing Risk for SUDS across Multiple Cohorts

- 514 39. Barr, P. B. & Dick, D. M. The Genetics of Externalizing Problems. *Current Topics in*
515 *Behavioral Neurosciences* **47**, 93–112 (2020).
- 516 40. Krueger, R. F. *et al.* Etiological connections among substance dependence, antisocial
517 behavior and personality: Modeling the externalizing spectrum. *J Abnorm Psychol* **111**,
518 411–424 (2002).
- 519 41. Kendler, K. S. & Myers, J. The boundaries of the internalizing and externalizing genetic
520 spectra in men and women. *Psychological Medicine* **44**, 647–655 (2014).
- 521 42. Polimanti, R. *et al.* Evidence of causal effect of major depression on alcohol dependence:
522 Findings from the psychiatric genomics consortium. *Psychological Medicine* (2019)
523 doi:10.1017/S0033291719000667.
- 524 43. Johnson, E. C. *et al.* A large-scale genome-wide association study meta-analysis of
525 cannabis use disorder. *The Lancet Psychiatry* (2020) doi:10.1016/S2215-0366(20)30339-
526 4.
- 527 44. Zhou, H. *et al.* Association of OPRM1 Functional Coding Variant With Opioid Use
528 Disorder: A Genome-Wide Association Study. *JAMA Psychiatry* (2020)
529 doi:10.1001/jamapsychiatry.2020.1206.
- 530 45. Kendler, K. S., Gardner, C. & Dick, D. M. Predicting alcohol consumption in adolescence
531 from alcohol- specific and general externalizing genetic risk factors, key environmental
532 exposures and their interaction. *Psychol Med* **41**, 1507–1516 (2011).
- 533 46. Meyers, J. L. *et al.* Genetic Influences on Alcohol Use Behaviors Have Diverging
534 Developmental Trajectories□: A Prospective Study Among Male and Female Twins.
535 *Alcoholism: Clinical and Experimental Research* **38**, 2869–2877 (2014).
- 536 47. Barr, P. B. *et al.* Parsing Genetically Influenced Risk Pathways: Genetic Loci Impact
537 Problematic Alcohol Use Via Externalizing and Specific Risk. *medRxiv*
538 2021.07.20.21260861 (2021) doi:10.1101/2021.07.20.21260861.

Running Header: Characterizing Risk for SUDS across Multiple Cohorts

- 539 48. Sanchez-Roige, S., Palmer, A. A. & Clarke, T. K. Recent Efforts to Dissect the Genetic
540 Basis of Alcohol Use and Abuse. *Biological Psychiatry* (2020)
541 doi:10.1016/j.biopsych.2019.09.011.
- 542 49. Walters, R. K. *et al.* Trans-ancestral GWAS of alcohol dependence reveals common
543 genetic underpinnings with psychiatric disorders. *Nature Neuroscience* **21**, 1656–1669
544 (2018).
- 545 50. Dick, D. M., Barr, P., Guy, M., Nasim, A. & Scott, D. Review: Genetic research on alcohol
546 use outcomes in African American populations: A review of the literature, associated
547 challenges, and implications. *American Journal on Addictions* vol. 26 486–493 (2017).
- 548 51. Mills, M. C. & Rahal, C. A scientometric review of genome-wide association studies.
549 *Communications Biology* **2**, 9 (2019).
- 550 52. Martin, A. R. *et al.* Human Demographic History Impacts Genetic Risk Prediction across
551 Diverse Populations. *Am J Hum Genet* **100**, 635–649 (2017).
- 552 53. Duncan, L. *et al.* Analysis of polygenic risk score usage and performance in diverse
553 human populations. *Nature Communications* (2019) doi:10.1038/s41467-019-11112-0.
- 554 54. Ruan, Y. *et al.* Improving Polygenic Prediction in Ancestrally Diverse Populations. *Nature*
555 *Genetics* (2022) doi:10.1038/s41588-022-01054-7.
- 556 55. Curran, P. J. & Hussong, A. M. Integrative Data Analysis: The Simultaneous Analysis of
557 Multiple Data Sets. *Psychological Methods* **14**, 81–100 (2009).
- 558 56. Cameron, C. A., Gelbach, J. B. & Miller, D. L. Robust inference with multiway clustering.
559 *Journal of Business and Economic Statistics* **29**, 238–249 (2011).
- 560 57. Nagelkerke, N. J. D. A note on a general definition of the coefficient of determination.
561 *Biometrika* **78**, 691–692 (1991).
- 562 58. Hasin, D. S. & Grant, B. F. The National Epidemiologic Survey on Alcohol and Related
563 Conditions (NESARC) Waves 1 and 2: review and summary of findings. *Social Psychiatry*
564 *and Psychiatric Epidemiology* **50**, 1609–1640 (2015).

Running Header: Characterizing Risk for SUDS across Multiple Cohorts

- 565 59. Kong, A. *et al.* The nature of nurture: Effects of parental genotypes. *Science (1979)* **359**,
566 424–428 (2018).
- 567 60. Conrod, P. J. *et al.* Effectiveness of a Selective, Personality-Targeted Prevention
568 Program for Adolescent Alcohol Use and Misuse: A Cluster Randomized Controlled Trial.
569 *JAMA Psychiatry* **70**, 334–342 (2013).
- 570 61. Burt, S. A. Are there meaningful etiological differences within antisocial behavior? Results
571 of a meta-analysis. *Clin Psychol Rev* **29**, 163–178 (2009).
- 572 62. Rhee, S. H. & Waldman, I. D. Genetic and environmental influences on antisocial
573 behavior: A meta-analysis of twin and adoption studies. *Psychol Bull* **128**, 490–529
574 (2002).
- 575 63. Garg, A., Boynton-Jarrett, R. & Dworkin, P. H. Avoiding the Unintended Consequences of
576 Screening for Social Determinants of Health. *JAMA* **316**, 813–814 (2016).
- 577 64. Davidson, K. W. & McGinn, T. Screening for Social Determinants of Health: The Known
578 and Unknown. *JAMA* **322**, 1037–1038 (2019).
- 579 65. Martin, A. R. *et al.* Clinical use of current polygenic risk scores may exacerbate health
580 disparities. *Nature Genetics* **51**, 584–591 (2019).
- 581 66. Williams, D. R., Mohammed, S. A., Leavell, J. & Collins, C. Race, socioeconomic status,
582 and health: complexities, ongoing challenges, and research opportunities. *Ann N Y Acad*
583 *Sci* **1186**, 69–101 (2010).
- 584
- 585

Running Header: Characterizing Risk for SUDS across Multiple Cohorts

586

Table 1: Items included in the Clinical/Environmental Risk Index (CERI)

| Measure | Definition |
|--------------------------------------|---|
| 1) Low childhood SES | Parent(s) report having less than basic level of education [culturally dependent]; having a low-skill or menial occupation; income at or below the poverty line; or receipt of government assistance. |
| 2) Family history of SUD | Biological parent self-reports history of SUD for themselves or other biological parent or meets criteria for SUD from clinical interview/AUDIT threshold of 8 or higher. |
| 3) Childhood externalizing problems | Respondent meets criteria for conduct disorder or oppositional defiant disorder from a clinical interview or computer-based prediction; or has a behavior problems score at or above the 90th percentile at 15 or younger. |
| 4) Childhood internalizing problems | Respondent reports diagnosis of depression/anxiety or panic disorder; meets criteria for internalizing disorder in clinical interview/computer-based prediction; or has a CES-D score above a threshold of 16 at 15 or younger. |
| 5) Early initiation of substance use | Respondent reports age of first whole alcoholic drink, smoked whole cigarette, or tried cannabis before the age of 15. |
| 6) Adolescent alcohol use | Frequency of self-reported use 5 or more days per week at age 18 and below. |
| 7) Adolescent tobacco use | Frequency of self-reported use at daily use at age 18 and below. |
| 8) Adolescent cannabis use | Frequency of self-reported use 5 or more days per week at age 18 and below. |
| 9) Peer substance use | Respondent reports the majority of their best friends use alcohol/tobacco/cannabis; their three best friends smoke daily/drink once a month/use cannabis once a month; or more than one friend smokes/drinks alcohol/has tried other drugs. |
| 10) Traumatic events | Respondent reports exposure to any traumatic event. |

587 Full description of sample specific definitions available in the supplementary information.

Table 2: Prevalence of SUDs and CERI by Cohort

| | <i>Add Health</i> AFR (N = 1,605)* | | <i>Add Health</i> EUR (N = 4,855)* | | <i>ALSPAC</i> EUR (N = 4,733)* | | <i>COGA</i> AFR (N = 870)* | | <i>COGA</i> EUR (N = 1,878)* | | <i>FinnTwin12</i> EUR (N = 1,193)* | |
|---------------------------------------|--|--------|--|--------|--------------------------------------|--------|----------------------------------|--------|------------------------------------|--------|--|--------|
| | <u>Mean (SD)/%</u> | | <u>Mean (SD)/%</u> | | <u>Mean (SD)/%</u> | | <u>Mean (SD)/%</u> | | <u>Mean (SD)/%</u> | | <u>Mean (SD)/%</u> | |
| Female | 55.26% | - | 53.59% | - | 56.71% | - | 51.38% | - | 51.33% | - | 53.73% | - |
| Age (at last observation) | 28.89 | (1.69) | 28.84 | (1.70) | 22.47 | (2.20) | 24.13 | (5.12) | 24.24 | (5.26) | 22.44 | (0.72) |
| Alcohol dependence | 3.93% | - | 12.75% | - | 5.92% | - | 11.49% | - | 21.14% | - | 8.55% | - |
| Nicotine dependence | 2.74% | - | 10.28% | - | 1.54% | - | 3.91% | - | 7.83% | - | 2.26% | - |
| Drug dependence | 6.73% | - | 10.79% | - | 0.78% | - | 26.44% | - | 23.59% | - | 1.34% | - |
| Any substance dependence [†] | 11.21% | - | 25.81% | - | 8.87% | - | 30.69% | - | 34.66% | - | 10.98% | - |
| CERI | 1.95 | (1.48) | 2.07 | (1.65) | 2.08 | (1.19) | 3.98 | (2.24) | 3.65 | (2.38) | 2.62 | (1.27) |

* Available samples with genotypic, phenotypic, and environmental risk data

[†] Any substance dependence includes those who meet criteria for alcohol, nicotine, or drug dependence.

AFR = African ancestries; EUR = European ancestries; CERI = clinical/environmental risk index

588
589
590

Table 3: Estimates for PGS Only, CERI Only, and Combined Models

| | | Alcohol Dependence | | | Nicotine Dependence | | | Drug Dependence | | | Any substance dependence | | |
|---------------------|---------------------|--------------------|---------------------|-----------|---------------------|---------------------|-----------|-----------------|---------------------|-----------|--------------------------|---------------------|-----------|
| | | <u>OR</u> | <u>95% CI</u> | <u>CI</u> | <u>OR</u> | <u>95% CI</u> | <u>CI</u> | <u>OR</u> | <u>95% CI</u> | <u>CI</u> | <u>OR</u> | <u>95% CI</u> | <u>CI</u> |
| PGS Only Model* | ALCC PGS | 1.05 | (0.99, 1.11) | | 0.96 | (0.89, 1.04) | | 1.05 | (0.98, 1.12) | | 1.00 | (0.96, 1.05) | |
| | ALCP PGS | 1.13 | (1.06, 1.20) | | 1.01 | (0.93, 1.10) | | 1.07 | (1.00, 1.15) | | 1.10 | (1.05, 1.16) | |
| | EXT PGS | 1.18 | (1.11, 1.26) | | 1.50 | (1.38, 1.63) | | 1.27 | (1.19, 1.36) | | 1.31 | (1.25, 1.38) | |
| | MDD PGS | 1.00 | (0.94, 1.06) | | 1.06 | (0.98, 1.15) | | 1.08 | (1.02, 1.15) | | 1.02 | (0.98, 1.07) | |
| | SCZ PGS | 1.04 | (0.97, 1.10) | | 0.98 | (0.90, 1.06) | | 1.03 | (0.96, 1.11) | | 1.00 | (0.96, 1.05) | |
| | CPD PGS | 1.00 | (0.94, 1.06) | | 1.33 | (1.24, 1.43) | | 1.01 | (0.95, 1.08) | | 1.08 | (1.03, 1.13) | |
| | $\Delta Pseudo-R^2$ | | | 0.011 | | | 0.037 | | | 0.014 | | | 0.022 |
| CERI Only Model* | CERI | 1.37 | (1.33, 1.41) | | 1.63 | (1.57, 1.70) | | 1.67 | (1.61, 1.72) | | 1.58 | (1.54, 1.63) | |
| $\Delta Pseudo-R^2$ | | | 0.054 | | | 0.107 | | | 0.129 | | | 0.120 | |
| Combined Model* | CERI | 1.35 | (1.31, 1.40) | | 1.58 | (1.52, 1.65) | | 1.65 | (1.59, 1.70) | | 1.55 | (1.51, 1.60) | |
| | ALCC PGS | 1.04 | (0.97, 1.10) | | 0.94 | (0.87, 1.03) | | 1.03 | (0.96, 1.11) | | 0.99 | (0.94, 1.04) | |
| | ALCP PGS | 1.12 | (1.05, 1.19) | | 0.99 | (0.91, 1.08) | | 1.06 | (0.98, 1.14) | | 1.09 | (1.04, 1.15) | |
| | EXT PGS | 1.08 | (1.01, 1.15) | | 1.33 | (1.22, 1.45) | | 1.11 | (1.03, 1.20) | | 1.18 | (1.12, 1.24) | |
| | MDD PGS | 0.97 | (0.91, 1.03) | | 1.02 | (0.94, 1.10) | | 1.03 | (0.96, 1.10) | | 0.98 | (0.93, 1.03) | |
| | SCZ PGS | 1.03 | (0.97, 1.10) | | 0.96 | (0.88, 1.05) | | 1.01 | (0.94, 1.08) | | 1.00 | (0.95, 1.05) | |
| | CPD PGS | 0.98 | (0.92, 1.04) | | 1.31 | (1.22, 1.42) | | 0.98 | (0.92, 1.04) | | 1.06 | (1.01, 1.11) | |
| $\Delta Pseudo-R^2$ | | | 0.059 | | | 0.126 | | | 0.131 | | | 0.128 | |

* All models included age, sex, and cohort as covariates. See Supplemental Table 7 for all parameter estimates. PGS residualized on age, sex, and first 10 ancestral principal components.

Bolded estimates = $p < .05$ after correction for multiple testing ($p < .05/4 = 0.0125$)

$\Delta Pseudo-R^2$ denotes pseudo- R^2 above model including age, sex, and cohort. CI = confidence interval; PGS = polygenic score; CERI = clinical/environmental risk index

591 **FIGURE CAPTIONS**

592 *Figure 1: SUD Prevalence Across Genetic and Environmental Risk Factors*


593 Panel A: Prevalence (and 95% confidence intervals) of those who meet criteria for alcohol,
594 nicotine, drug, or any substance dependence across counts for items in the risk index. Panel B:
595 Prevalence (and 95% confidence intervals) of those who meet criteria for alcohol, nicotine, drug,
596 or any substance dependence across four categories: 1) those below the 90th percentile for all
597 PGS and the CERI; 2) those at or above the 90th percentile for the CERI; 3) those at or above
598 the 90th percentile for all PGS; and 4) those at or above the 90th percentile for both the CERI
599 and PGS. PGS and risk index were first residualized on sex, age, age², cohort, sex*age,
600 sex*age², sex*cohort, cohort*age, cohort*age², sex*cohort*age, and sex*cohort*age². Dotted
601 colored lines represent corresponding lifetime prevalence estimates for alcohol dependence
602 (red), nicotine dependence (green), drug dependence (blue), and any substance use disorder
603 (purple) from nationally representative data⁵⁸.

604


605 *Figure 2: ROC Curves for Combined and Baseline Models*

606 Receiver operating characteristic (ROC) curves for baseline models (red line, covariates only)
607 and the full models (blue line, PGS + CERI + covariates) for each substance use disorder. Area
608 under the curve (AUC) is presented for the PGS model in each cell. Change in AUC represents
609 value of the difference between AUC from the full model and AUC from the base model.


A




B




Alcohol Dependence




Nicotine Dependence



Drug Dependence



Any Substance Dependence



1 - Specificity

Model — Base - - Full